Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.
Payne AB, Battan-Wraith S, Rowley EAK, Stockwell MS, Tartof SY, Dascomb K, Irving SA, Dixon B, Ball SW, Tenforde MW, Vazquez-Benitez G, Stephens AB, Han J, Natarajan K, Salas SB, Bezi C, Sy LS, Lewin B, Sheffield T, Arndorfer J, Bride D, Van Otterloo J, Naleway AL, Koppolu PD, Grannis S, Fadel W, Rogerson C, Duszynski T, Reese SE, Mitchell PK, Chickery S, Moline HL, Najdowski M, Ciesla AA, Reeves EL, DeSilva M, Fleming-Dutra KE, Link-Gelles R.
Payne AB, et al. Among authors: ciesla aa.
Lancet Reg Health Am. 2025 Aug 6;49:101196. doi: 10.1016/j.lana.2025.101196. eCollection 2025 Sep.
Lancet Reg Health Am. 2025.
PMID: 41040536
Free PMC article.